Tadalafil Peptide vs TriMix
A side-by-side research comparison of Tadalafil Peptide and TriMix across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Tadalafil Peptide | TriMix |
|---|---|---|
| Full name | Tadalafil-Peptide Conjugate (Experimental) | TriMix (Papaverine + Phentolamine + Alprostadil) |
| Category | Sexual Health | Sexual Health |
| Status | Research compound | Compounded medication |
| Mechanism | CPP moiety facilitates targeted PDE5 inhibitor delivery to penile smooth muscle. Local PDE5 inhibition increases cGMP for NO-mediated vasodilation with reduced systemic exposure. | Papaverine relaxes smooth muscle via PDE inhibition. Phentolamine blocks alpha-adrenergic receptors. Alprostadil (PGE1) directly stimulates cAMP production in cavernosal tissue. Together they produce reliable penile erection independent of arousal. |
| Molecular weight | ~2,500 Da (conjugate) | Combination compound |
| Half-life | 8-12 hours | ~1-3 hours (local effect) |
| Bioavailability | Targeted (topical/local) | Direct intracavernosal: ~100% |
| Typical dose | 1-5 mg equivalent | 0.1-0.5 mL (titrated) |
| Frequency | As needed | As needed, max 3x/week |
| Route | Topical or local injection | Intracavernosal injection |
Tadalafil Peptide reported benefits
- Targeted PDE5 inhibition
- Reduced systemic side effects
- Potentially faster onset
- Lower dose requirement
TriMix reported benefits
- Reliable erectile response
- Works when oral meds fail
- Rapid onset (5-15 min)
- Adjustable dosing
- No systemic cardiovascular effects
Related comparisons
Research and educational reference only. Not medical advice.